---
document_datetime: 2024-11-20 16:57:27
document_pages: 10
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/tenkasi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: tenkasi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 6.5931857
conversion_datetime: 2025-12-24 18:45:52.738335
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Tenkasi

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                         | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                           |
|----------------------|---------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------|
| IA/0046              | A.7 - Administrative change - Deletion of manufacturing sites | 19/11/2024                          |                                             | Annex II and PL                  |                                   |
| PSUSA/10368 /202403  | Periodic Safety Update EU Single assessment - oritavancin     | 03/10/2024                          | n/a                                         |                                  | PRAC Recommendation - maintenance |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| IA/0045             | B.I.c.z - Container closure system of the AS - Other variation                                                                                                                                                                                                                                                                                                                               | 05/08/2024   | n/a        |                        |                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-----------------------------------|
| IAIN/0044/G         | This was an application for a group of variations. B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site | 10/06/2024   |            | Annex II and PL        |                                   |
| IA/0042             | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                | 09/11/2023   | n/a        |                        |                                   |
| PSUSA/10368 /202303 | Periodic Safety Update EU Single assessment - oritavancin                                                                                                                                                                                                                                                                                                                                    | 26/10/2023   | n/a        |                        | PRAC Recommendation - maintenance |
| IA/0041             | B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the dossier) - Deletion of a supplier                                                                                                                                                                                                                                                                  | 17/10/2023   | n/a        |                        |                                   |
| X/0036              | Annex I_2.(c) Change or addition of a new strength/potency                                                                                                                                                                                                                                                                                                                                   | 22/06/2023   | 15/09/2023 | SmPC, Labelling and PL |                                   |
| IB/0040             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                | 25/08/2023   | n/a        |                        |                                   |

<div style=\"page-break-after: always\"></div>

| II/0037   | Extension of indication to include treatment of paediatric population, aged between 3 months and less than 18 years for Tenkasi (oritavancin) 400 mg based on interim results from study TMC-ORI-11-01. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2 and 6.6 of the SmPC were updated. The Package Leaflet is updated in accordance. In addition, the MAH has taken the opportunity to make minor editorial amendments and QRD updates (v10.2) to the SmPC/PL.. Furthermore, the PI is brought in line with the latest QRD template version 10.2 rev 1. Version 5.1 of the RMP has also been approved. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one   | 30/03/2023   | 15/05/2023   | SmPC and PL   | Please refer to Scientific Discussion 'Tenkasi-H-C-003785- II-0037'.   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|---------------|------------------------------------------------------------------------|
| IB/0038/G | This was an application for a group of variations. B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 25/11/2022   | n/a          |               |                                                                        |
| IA/0035/G | This was an application for a group of variations. B.II.c.1.c - Change in the specification parameters and/or limits of an excipient - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.II.c.1.c - Change in the specification parameters and/or limits of an excipient - Deletion of a non-                                                                                                                                                                                                                                                                                                                                                                                                           | 09/02/2022   | n/a          |               |                                                                        |

<div style=\"page-break-after: always\"></div>

|                     | significant specification parameter (e.g. deletion of an obsolete parameter)                                                                                                                                                                                                                                                                                  |            |            |                        |                                                                                                                                            |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0034           | A.2.a - Administrative change - Change in the (invented) name of the medicinal product for CAPs                                                                                                                                                                                                                                                               | 09/08/2021 | 15/03/2023 | SmPC, Labelling and PL |                                                                                                                                            |
| IA/0033/G           | This was an application for a group of variations. B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                  | 26/05/2021 | n/a        |                        |                                                                                                                                            |
| PSUSA/10368 /202003 | Periodic Safety Update EU Single assessment - oritavancin                                                                                                                                                                                                                                                                                                     | 15/10/2020 | 09/12/2020 | SmPC and PL            | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10368/202003. |
| IB/0032             | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                                                                        | 08/12/2020 | n/a        |                        |                                                                                                                                            |
| II/0030             | Submission of the final report from 14-TMC-01, a Surveillance study investigation, listed as a category 3 study in the RMP, part of the global SENTRY Antimicrobial Surveillance Program platform to monitor the activity of oritavancin against Gram- positive clinical isolates collected from Europe and the US. This application addresses PAM MEA 003.4, | 26/11/2020 | n/a        |                        |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|                     | presenting the cumulative surveillance data from 2010 to 2019 (including the first 5-year post- approval period). The RMP version 3.1 is approved with this variation. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority   |            |            |                                  |                                                                                                                                                                                                                                                                        |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0029             | B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter)                                                                                                    | 06/04/2020 | n/a        |                                  |                                                                                                                                                                                                                                                                        |
| IB/0028             | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                              | 30/03/2020 | 09/12/2020 | SmPC                             |                                                                                                                                                                                                                                                                        |
| R/0027              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                | 14/11/2019 | 13/01/2020 | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Orbactiv in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| PSUSA/10368 /201903 | Periodic Safety Update EU Single assessment - oritavancin                                                                                                                                                                                                                                                              | 17/10/2019 | 18/12/2019 | SmPC and PL                      | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10368/201903.                                                                                                                             |
| IAIN/0026/G         | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                       | 14/06/2019 | 18/12/2019 | Annex II and PL                  |                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

|                     | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing   |            |            |                        |                                   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------|
| PSUSA/10368 /201809 | Periodic Safety Update EU Single assessment - oritavancin                                                                                                                                                                                                                                                                                   | 11/04/2019 | n/a        |                        | PRAC Recommendation - maintenance |
| IA/0024/G           | This was an application for a group of variations. B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                | 17/03/2019 | n/a        |                        |                                   |
| N/0023              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                            | 22/02/2019 | 18/12/2019 | Labelling              |                                   |
| T/0022              | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                         | 06/12/2018 | 11/01/2019 | SmPC, Labelling and PL |                                   |
| PSUSA/10368 /201803 | Periodic Safety Update EU Single assessment - oritavancin                                                                                                                                                                                                                                                                                   | 04/10/2018 | n/a        |                        | PRAC Recommendation - maintenance |
| T/0020              | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                         | 12/07/2018 | 13/08/2018 | SmPC,                  |                                   |

<div style=\"page-break-after: always\"></div>

|                     |                                                                                                                                                                                                                                              |            |            | Labelling and PL   |                                                                                                                                                                                                                                                                                                                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10368 /201709 | Periodic Safety Update EU Single assessment - oritavancin                                                                                                                                                                                    | 26/04/2018 | 25/06/2018 | SmPC and PL        | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10368/201709.                                                                                                                                                                                        |
| IAIN/0018           | C.I.11.a - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of wording agreed by the competent authority                                                    | 11/04/2018 | n/a        |                    |                                                                                                                                                                                                                                                                                                                                   |
| PSUSA/10368 /201703 | Periodic Safety Update EU Single assessment - oritavancin                                                                                                                                                                                    | 28/09/2017 | n/a        |                    | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                 |
| PSUSA/10368 /201609 | Periodic Safety Update EU Single assessment - oritavancin                                                                                                                                                                                    | 06/04/2017 | n/a        |                    | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                 |
| IA/0014             | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient | 12/12/2016 | n/a        |                    |                                                                                                                                                                                                                                                                                                                                   |
| PSUSA/10368 /201603 | Periodic Safety Update EU Single assessment - oritavancin                                                                                                                                                                                    | 29/09/2016 | n/a        |                    | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                 |
| II/0012/G           | This was an application for a group of variations. Group of variations consisting of: 1. Update of sections 4.4 and 4.5 of the SmPC in order to delete the warning related to the interaction with warfarin and include the results of the   | 15/09/2016 | 12/12/2016 | SmPC and PL        | Update of sections 4.4 and 4.5 of the SmPC in order to delete the warning related to the interaction with warfarin and include the results of the new interaction study (MDCO-ORI-14-02). This study was to assess the drug- drug interaction effect of a single 1200mg dose of oritavancin on the pharmacokinetics of S-warfarin |

<div style=\"page-break-after: always\"></div>

|                     | interaction study (MDCO-ORI-14-02) , respectively. The Package Leaflet and RMP (version 2.2) are updated in accordance. 2. Update of the RMP (version 2.2) to delete the category 3 study MDCO-ORI-14-03 C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required   |            |     | following a single dose was conducted in 36 healthy subjects. S-warfarin pharmacokinetics were evaluated following a single dose of warfarin 25mg given alone, or administered at the start, 24, or 72 hours after a single 1200mg dose of oritavancin. The results showed no effect of oritavancin on S-warfarin exposure (AUC) and maximum concentration (Cmax).   |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10368 /201509 | Periodic Safety Update EU Single assessment - oritavancin                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 14/04/2016 | n/a | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                    |
| IB/0010             | B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products                                                                                                                                                                                                                                                                                                                                                                                   | 30/03/2016 | n/a |                                                                                                                                                                                                                                                                                                                                                                      |
| II/0008             | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 17/03/2016 | n/a |                                                                                                                                                                                                                                                                                                                                                                      |
| IB/0009             | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 05/02/2016 | n/a |                                                                                                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

| IB/0007   | - Introduction of, or change(s) to, the and conditions of a marketing including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 22/12/2015   | n/a        |             | C.I.11.z obligations authorisation,   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|---------------------------------------|
| II/0003   | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 17/12/2015   | 12/12/2016 | SmPC and PL |                                       |
| IB/0005/G | This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor approved test procedure | 30/10/2015   | n/a        |             | changes to an                         |
| IA/0004/G | This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 14/10/2015   | n/a        |             |                                       |

<div style=\"page-break-after: always\"></div>

|         | B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits   |            |     |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| II/0002 | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority     | 17/09/2015 | n/a |
| IB/0001 | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation     | 22/05/2015 | n/a |